Early Access — free while we kick the tires
EdgarHawk

USPH U S PHYSICAL THERAPY INC /NV Insider Trading

Latest: Director Bought $49K of Shares · Jun 2026

U S PHYSICAL THERAPY INC /NV (USPH)'s reported leadership includes CEO Christopher Reading. Its Form 4 history breaks down as 3 buys and 0 sells, filed by 2 distinct insiders through Jun 2026. Its highest-significance filing in the last 90 days: Director Peter Francis Minan bought $49K, transaction dated Jun 2026.

3 filings analyzed · Latest 2026-06-10

Get alerts for USPH

Free Form 4 email alerts, scored for significance — see how.

Buys
3
Sells
0
Insiders
2
Direction
Net buying

U S PHYSICAL THERAPY INC /NV leadership

CEO
Christopher Reading — Chief Executive Officer
CFO
Jason Curtis — Chief Financial Officer
COO
Eric J. Williams — President and Chief Operating Officer - East
General Counsel
Richard S. Binstein — Executive Vice President, General Counsel and Secretary
Chair
Christopher J. Reading — Chairman of the Board of Directors and Chief Executive Officer

Historically, medium-priority insider buys have outperformed the S&P 500 by a median ~1% over the 30 days after the trade — the edge is concentrated in that first month (n ≈ 7,162, 2024-2026). Past results don't predict the future. How we measure this ↗

June 2026
2026-06-10
medium
780 shares
$48,777
@ $62.53
Significance 6

Director Peter Francis Minan buys 780 shares at $62.53 avg, raising stake to 3,211 shares (+32.1%)

Director Peter Francis Minan executed 2 separate purchases totaling 780 shares for $48,776.88 on June 8-9, 2026, at a blended average price of $62.53. His post-transaction holdings of 3,211 shares represent a net change of purchased 780 shares (+32.1% vs pre-transaction holdings). The stock's 52-week range is $58.19–$93.50, placing the transaction price $62.53 near the lower end of that range, though current price of $62.83 is -32.8% from the 52-week high and +5.7% over the prior 30 days. The insider's cross-ticker track record shows 1 prior buy, making this his second recorded open-market purchase. Company fundamentals show revenue of $198,286,000.00 with net income of $5,038,000.00, annual revenue growth of +16.3%, and a P/E ratio of 27.56.

November 2025
2025-11-24
high
4,000 shares
$276,000
@ $69.00
Significance 7

Director Kathleen A Gilmartin bought 4,000 shares of USPH at $69.00 on 2025-11-20; stock down 28.4% from 52-week high.

Director Kathleen A Gilmartin purchased 4,000 shares at $69.00, increasing her holdings by 19.2% to 24,786 shares. This marks her third open-market purchase at USPH, and her prior two purchases at this ticker demonstrated favorable 90-day outcomes: +15.4% (2024-09-03 buy) and +13.9% (2023-11-10 buy). The current transaction occurs as the stock trades at $71.50, down 28.4% from its 52-week high of $99.91 and down 23.2% over the prior 30 days, while the company maintains solid fundamentals with $197.1M in latest quarterly revenue, $13.1M in net income, and 11.0% annual revenue growth. Her cross-ticker track record shows a 100% win rate on 90-day returns across 2 prior buys (avg +14.7%), suggesting consistent ability to identify value entry points, though this new position's timing relative to near-term technicals and sentiment requires monitoring against the company's earnings trajectory.

September 2024
2024-09-03
medium
2,000 shares
$172,180
@ $86.09
Significance 6

Director Kathleen A. Gilmartin purchases 2,000 shares of USPH at $86.09; stock down 23.8% from 52-week high despite prior well-timed buy pattern.

Director Kathleen A. Gilmartin purchased 2,000 shares at $86.09 on 2024-09-03, increasing her holdings by 11.8% to 18,904 shares. This represents her second open-market purchase at USPH; her prior buy in November 2023 at this ticker delivered a 13.9% return over 90 days. However, the current purchase occurs against a backdrop of significant recent weakness: the stock has declined 9.2% over the prior 30 days and 13.2% over 90 days, placing it 23.8% below its 52-week high of $112.87. While her cross-ticker track record shows a 100% win rate with an average 90-day return of +13.9%, and her same-ticker history demonstrates well-timed buying (1 of 1 prior buys were well-timed at the 90-day mark), the company's elevated P/E of 50.88 against modest net income of $7.5M on revenue of $167.2M reflects a valuation structure that warrants observation of near-term price action relative to the insider's purchase thesis.

Insiders here also file at

More Health Services companies